YDES — YD Bio Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 1st Jan | Unit | 1966 | 1967 | 1968 | 1969 | 1970 | 1971E | 1972E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
YD Bio Ltd is a Taiwan-based company principally engaged in pioneering transformative solutions from early cancer detection to next-generation cell therapies to improve and extend patient lives. The Company’s core areas include non-invasive cancer detection tools for early diagnosis and monitoring, ophthalmologic products targeting dry eye conditions, and exosome-based therapeutics aimed at treating complex diseases. By integrating cutting-edge science with accessible solutions, YD Bio strives to improve patient outcomes and quality of life.
Directors
- Last Annual
- January 1st, 1970
- Last Interim
- January 1st, 1970
- Incorporated
- November 15th, 2024
- Public Since
- August 29th, 2025
- No. of Shareholders
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 70,319,824
- Address
- 2F, TAIPEI, 115
- Web
- http://ir.ydesgroup.com/
- Phone
- +886 23820330
- Auditors
- Marcum LLP
Similar to YDES
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 19:26 UTC, shares in YD Bio are trading at $16.39. This share price information is delayed by 15 minutes.
Shares in YD Bio last closed at $16.39 and the price had moved by +45.82% over the past 365 days. In terms of relative price strength the YD Bio share price has outperformed the S&P500 Index by +23.99% over the past year.
There is no consensus recommendation for this security.
Find out moreYD Bio does not currently pay a dividend.
YD Bio does not currently pay a dividend.
YD Bio does not currently pay a dividend.
To buy shares in YD Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $16.39, shares in YD Bio had a market capitalisation of .
Here are the trading details for YD Bio:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: YDES
Based on an overall assessment of its quality, value and momentum YD Bio is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like YD Bio. Over the past six months, its share price has outperformed the S&P500 Index by +29.45%.
As of the last closing price of $16.39, shares in YD Bio were trading +41.74% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The YD Bio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $16.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on YD Bio's directors